# An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Source: https://onco.cc/trials/nct02213926/  
OnCo record `nct02213926` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acalabrutinib in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT02213926 by Acerta Pharma BV, with 124 participants enrolled, started 2015-03-02 and due to reach its primary completion in 2020-12-04. Interventions recorded: ACP-196 (acalabrutinib). Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02213926
- Phase: 2
- Setting: An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
- Sponsor: Acerta Pharma BV
- Enrolled: 124

## Sources

- ClinicalTrials.gov NCT02213926: https://clinicaltrials.gov/study/NCT02213926

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct02213926.json